Want to see TSE:MYTC full AI Analyst Report?
MYTC Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)1.23K
Market Cap
C$146.74K
Enterprise ValueC$498.81K
Total Cash (Recent Filing)C$90.21K
Total Debt (Recent Filing)C$429.65K
Price to Earnings (P/E)―
Beta-7.57
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding29,348,236
10 Day Avg. Volume3,700
30 Day Avg. Volume1,233
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-7.02
Price to Sales (P/S)77.96
P/FCF Ratio-9.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginA sharp TTM improvement in gross margin suggests better unit economics or product mix that could sustain lower per-unit costs. If maintained, this structural improvement supports margin scalability as revenue stabilizes and reduces incremental cash burn needed to operate the business.
Lower Outstanding Debt Versus Prior YearsA declining debt load reduces interest expense and leverage, improving financial flexibility. Over the next several months this trend can extend runway and reduce refinancing risk, making it easier to fund R&D or commercialization without destabilizing capital structure.
Niche Neuromodulation Product FocusSpecialization in non‑invasive neurostimulation and software platforms provides structural advantages: higher technical and regulatory barriers, potential clinical partnerships, and recurring software/service revenue opportunities that can create durable competitive moats if clinical validation progresses.
Bears Say
Sharp Revenue DeclineA ~40% YoY TTM revenue decline is a durable red flag for product-market fit and commercial execution. Sustained top-line contraction impairs operating leverage, magnifies unit-cost absorption issues, and forces higher dependency on external financing to fund operations and clinical or go-to-market activities.
Negative Shareholders' EquityPersistent negative equity reflects cumulative losses and weak capitalization, limiting access to traditional financing and increasing counterparty and supplier risk. Over months this structural weakness can constrain strategic options and necessitate dilutive financings or debt that further strain balance sheet health.
Consistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow means the business relies on external funding to continue. Although burn improved versus 2022, ongoing cash consumption tied to losses limits investment capacity in commercialization or trials and raises the risk of future dilution or restrictive financing terms.
MyndTec, Inc. News
MYTC FAQ
What was MyndTec, Inc.’s price range in the past 12 months?
MyndTec, Inc. lowest stock price was <C$0.01 and its highest was C$0.10 in the past 12 months.
What is MyndTec, Inc.’s market cap?
MyndTec, Inc.’s market cap is C$146.74K.
When is MyndTec, Inc.’s upcoming earnings report date?
MyndTec, Inc.’s upcoming earnings report date is Nov 25, 2026 which is in 87 days.
How were MyndTec, Inc.’s earnings last quarter?
Currently, no data Available
Is MyndTec, Inc. overvalued?
According to Wall Street analysts MyndTec, Inc.’s price is currently Overvalued.
Does MyndTec, Inc. pay dividends?
MyndTec, Inc. does not currently pay dividends.
What is MyndTec, Inc.’s EPS estimate?
MyndTec, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MyndTec, Inc. have?
MyndTec, Inc. has 29,348,236 shares outstanding.
What happened to MyndTec, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MyndTec, Inc.?
Currently, no hedge funds are holding shares in TSE:MYTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MyndTec, Inc.
MyndTec Inc. is a medical technology firm dedicated to the research, development, and distribution of therapeutic solutions. Its primary focus is on individuals in Canada and the United States who experience paralysis resulting from stroke or spinal cord injuries. At the heart of its offerings is MyndMove, a flagship product that employs a non-invasive functional electrical stimulation (FES) approach. This intervention leverages the brain's neuroplasticity to foster the creation of new motor and sensory neural pathways, enabling patients to regain voluntary movement and enhance their independence in daily activities. It also empowers trained therapists to assist patients in improving conscious control over their limbs. Beyond therapies, MyndTec supplies its MyndMove and MyndSearch devices to clinics and research institutions, alongside selling essential treatment consumables. The company serves hospitals through a combination of direct sales efforts and an established network of distributors. Established in 2008, the company initially operated as Simple Systems Inc. before rebranding as MyndTec Inc. in April 2013. Its corporate headquarters are located in Mississauga, Canada.
Technical Analysis
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―